Price to Earnings (P/E)
since 2005
Difficulty: Beginner
Calculation
Gilead Sciences Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income (loss) attributable to Gilead1 (in millions) |
÷ | No. shares of common stock outstanding2 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2005 | 34.15 | = | 15.03 | ÷ | 0.44 | 0.44 | = | 814 | ÷ | 1,849,138,544 |
| Dec 31, 2006 | – | = | 17.65 | ÷ | -0.64 | -0.64 | = | -1,190 | ÷ | 1,858,655,664 |
| Dec 31, 2007 | 25.19 | = | 21.90 | ÷ | 0.87 | 0.87 | = | 1,615 | ÷ | 1,857,740,064 |
| Dec 31, 2008 | 20.29 | = | 22.40 | ÷ | 1.10 | 1.10 | = | 2,011 | ÷ | 1,821,909,204 |
| Dec 31, 2009 | 16.29 | = | 23.76 | ÷ | 1.46 | 1.46 | = | 2,636 | ÷ | 1,806,757,972 |
| Dec 31, 2010 | 10.68 | = | 19.49 | ÷ | 1.82 | 1.82 | = | 2,901 | ÷ | 1,590,529,288 |
| Dec 31, 2011 | 12.20 | = | 22.58 | ÷ | 1.85 | 1.85 | = | 2,804 | ÷ | 1,514,630,722 |
| Dec 31, 2012 | 25.20 | = | 42.89 | ÷ | 1.70 | 1.70 | = | 2,592 | ÷ | 1,522,392,518 |
| Dec 31, 2013 | 42.00 | = | 83.95 | ÷ | 2.00 | 2.00 | = | 3,075 | ÷ | 1,538,252,914 |
| Dec 31, 2014 | 12.85 | = | 104.43 | ÷ | 8.12 | 8.12 | = | 12,101 | ÷ | 1,489,401,683 |
| Dec 31, 2015 | 6.75 | = | 89.36 | ÷ | 13.25 | 13.25 | = | 18,108 | ÷ | 1,366,845,691 |
| Dec 31, 2016 | 6.83 | = | 70.50 | ÷ | 10.33 | 10.33 | = | 13,501 | ÷ | 1,307,066,900 |
| Dec 31, 2017 | 22.75 | = | 80.36 | ÷ | 3.53 | 3.53 | = | 4,628 | ÷ | 1,309,967,781 |
1 USD $
2 Data adjusted for splits and stock dividends.
3 Close price on the filing date of Gilead Sciences Inc.'s Annual Report.
Source: Based on data from Gilead Sciences Inc. Annual Reports
Comparison to Competitors
Gilead Sciences Inc., P/E, long-term trends, comparison to competitors
| Gilead Sciences Inc. | Abbott Laboratories | AbbVie Inc. | Allergan PLC | Amgen Inc. | Biogen Inc. | Bristol-Myers Squibb Co. | Celgene Corp. | Eli Lilly & Co. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2005 | 34.15 | 20.03 | – | 23.73 | 23.70 | 97.42 | 14.96 | 222.19 | 31.90 | 16.95 | 16.62 | 23.92 | – |
| Dec 31, 2006 | – | 48.17 | – | – | 25.43 | 74.03 | 34.64 | 291.07 | 22.40 | 17.02 | 21.57 | 9.18 | – |
| Dec 31, 2007 | 25.19 | 23.82 | – | 20.72 | 15.64 | 29.33 | 20.60 | 97.86 | 19.26 | 17.07 | 29.88 | 18.51 | – |
| Dec 31, 2008 | 20.29 | 17.11 | – | 12.77 | 12.06 | 19.92 | 7.68 | – | – | 11.67 | 6.53 | 10.25 | – |
| Dec 31, 2009 | 16.29 | 14.69 | – | 22.32 | 12.10 | 15.03 | 4.03 | 35.45 | 9.18 | 14.22 | 9.00 | 16.41 | – |
| Dec 31, 2010 | 10.68 | 15.68 | – | 37.46 | 10.53 | 15.80 | 13.99 | 27.99 | 7.86 | 12.23 | 116.63 | 18.63 | – |
| Dec 31, 2011 | 12.20 | 18.67 | – | 29.40 | 14.61 | 23.57 | 15.07 | 24.85 | 10.42 | 18.48 | 18.63 | 15.99 | – |
| Dec 31, 2012 | 25.20 | 9.24 | 11.51 | 111.88 | 15.68 | 26.95 | 30.56 | 28.41 | 14.99 | 19.64 | 20.94 | 13.51 | 21.42 |
| Dec 31, 2013 | 42.00 | 23.25 | 19.64 | – | 18.69 | 38.21 | 35.01 | 46.13 | 13.88 | 18.72 | 37.83 | 9.32 | 77.00 |
| Dec 31, 2014 | 12.85 | 31.30 | 55.08 | – | 22.96 | 31.27 | 49.80 | 49.41 | 33.06 | 17.15 | 13.94 | 23.03 | 118.44 |
| Dec 31, 2015 | 6.75 | 12.83 | 17.01 | 31.94 | 15.95 | 16.67 | 64.22 | 48.59 | 33.35 | 18.80 | 31.64 | 26.37 | 60.50 |
| Dec 31, 2016 | 6.83 | 55.16 | 16.54 | 5.60 | 16.03 | 15.41 | 20.56 | 44.99 | 32.39 | 20.08 | 46.14 | 28.10 | 42.64 |
| Dec 31, 2017 | 22.75 | 220.29 | 35.47 | – | 64.06 | 28.83 | 103.55 | 24.35 | – | 268.10 | 61.63 | 9.99 | 28.99 |
Source: Based on data from Gilead Sciences Inc. Annual Reports
Comparison to Pharmaceuticals & Biotechnology Sector
Gilead Sciences Inc., P/E, long-term trends, comparison to Pharmaceuticals & Biotechnology sector
| Gilead Sciences Inc. | Pharmaceuticals & Biotechnology | |
|---|---|---|
| Dec 31, 2005 | 34.15 | 21.28 |
| Dec 31, 2006 | – | 19.07 |
| Dec 31, 2007 | 25.19 | 20.66 |
| Dec 31, 2008 | 20.29 | 13.59 |
| Dec 31, 2009 | 16.29 | 11.74 |
| Dec 31, 2010 | 10.68 | 15.73 |
| Dec 31, 2011 | 12.20 | 16.98 |
| Dec 31, 2012 | 25.20 | 17.06 |
| Dec 31, 2013 | 42.00 | 20.82 |
| Dec 31, 2014 | 12.85 | 23.76 |
| Dec 31, 2015 | 6.75 | 19.56 |
| Dec 31, 2016 | 6.83 | 18.35 |
| Dec 31, 2017 | 22.75 | 40.95 |
Source: Based on data from Gilead Sciences Inc. Annual Reports
Comparison to Health Care Industry
Gilead Sciences Inc., P/E, long-term trends, comparison to Health Care industry
| Gilead Sciences Inc. | Health Care | |
|---|---|---|
| Dec 31, 2005 | 34.15 | 22.32 |
| Dec 31, 2006 | – | 19.60 |
| Dec 31, 2007 | 25.19 | 20.28 |
| Dec 31, 2008 | 20.29 | 14.13 |
| Dec 31, 2009 | 16.29 | 12.25 |
| Dec 31, 2010 | 10.68 | 15.47 |
| Dec 31, 2011 | 12.20 | 16.25 |
| Dec 31, 2012 | 25.20 | 16.69 |
| Dec 31, 2013 | 42.00 | 20.65 |
| Dec 31, 2014 | 12.85 | 23.84 |
| Dec 31, 2015 | 6.75 | 20.31 |
| Dec 31, 2016 | 6.83 | 19.29 |
| Dec 31, 2017 | 22.75 | 34.72 |
Source: Based on data from Gilead Sciences Inc. Annual Reports